Clik here to view.
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of new data from its broad...
View ArticleClik here to view.
Data of InnoCare’s Robust Pipelines Presented at the European Hematology...
BEIJING Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2023 Hybrid Congress. Oral Presentation: Orelabrutinib, an...
View ArticleClik here to view.
ZAP Surgical Announces Upcoming Installation of Novel Non-Invasive Brain...
SAN CARLOS, Calif. ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Dankook University Hospital (DKUH) in Cheonan, South Korea, is slated to...
View ArticleClik here to view.
Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement...
TOKYO & SAN DIEGO Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Cullgen Inc. (President and CEO: Ying Luo, Ph.D., “Cullgen”) today announced a research...
View ArticleClik here to view.
BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will present data on its Bruton’s...
View ArticleClik here to view.
Sojitz Signs Memorandum of Understanding for Strategic Alliance with HIROTSU...
TOKYOTOKYO The Sojitz Corporation (“Sojitz”) has signed a memorandum of understanding with HIROTSU Bioscience Inc. (“HIROTSU”), a developer and provider of N-NOSE®, a primary cancer screening test...
View ArticleClik here to view.
Takeda and HUTCHMED Announce Marketing Authorization Application of...
OSAKA, Japan & CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J. Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM: HCM, HKEX: 13) (HUTCHMED) today...
View ArticleClik here to view.
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The...
OSAKA, Japan & CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J. Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (HUTCHMED) today...
View ArticleClik here to view.
Latest Data of InnoCare’s Orelabrutinib Presented at the 17th International...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, today announced the latest clinical data of its Bruton Tyrosine Kinase (BTK) inhibitor orelabrutinib at the...
View ArticleClik here to view.
武田薬品とハチメッド、治療歴のある転移性大腸がんに対するフルキンチニブの販売許可申請を欧州医薬品庁が審査中と発表
大阪、米マサチューセッツ州ケンブリッジ、香港、上海、米ニュージャージー州フローハムパーク （ビジネスワイヤ） –...
View ArticleClik here to view.
武田薬品とハッチメッド、へのFRESCO-2第3相試験の結果掲載を発表Lancet
大阪、マサチューセッツ州ケンブリッジ、香港、上海、ニュージャージー州フローラムパーク （ビジネスワイヤ） – 武田薬品（東京証券取引所：4502/ニューヨーク証券取引所：TAK）およびHUTCHMED (China)...
View ArticleClik here to view.
Children’s Hospital Los Angeles：美国加州和太平洋地区最佳的儿科医疗机构
洛杉矶 (美国商业资讯)–为儿童提供改变生活的专业医疗服务，是 Children’s Hospital Los Angeles (CHLA) 120 多年来的核心使命，无论是癌症治疗、脊柱侧凸手术、双器官移植或手臂骨折修复等方面，都体现了我们的实力。CHLA 已经连续 15 年蝉联《美国新闻与世界报道》评选的美国儿科护理顶级医院之列。在该权威报道于今日发布的 2023-24...
View ArticleClik here to view.
ICPO Foundation and FMRI Enter Strategic Partnership to Promote International...
WIESBADEN, Germany & GURGAON, India The International Centers for Precision Oncology (ICPO) Foundation and Fortis Memorial Research Institute (FMRI) today announced a reference center...
View ArticleClik here to view.
Kite Announces Completion of Marketing Authorization Transfer for Yescarta®...
SANTA MONICA, Calif. Kite Pharma, Inc., a Gilead Company (Nasdaq: GILD), today announced that the Marketing Authorization in Japan for Yescarta® (axicabtagene ciloleucel), a chimeric antigen...
View ArticleClik here to view.
CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase...
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and...
View ArticleClik here to view.
Thermo Fisher Scientific推出肿瘤培养基，加速新型癌症治疗方法的开发
加州卡尔斯巴德 (美国商业资讯)– 全球科学服务领导企业Thermo Fisher Scientific今日宣布推出Gibco™ OncoPro™肿瘤培养基试剂盒*，这是首个专门为多种癌症类型的患者源性肿瘤球或肿瘤类器官结构扩增而开发的商用培养基。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
サーモフィッシャーサイエンティフィック、腫瘍オルガノイド培養液を発表、新規がん治療開発を加速へ
カリフォルニア州カールスバッド （ビジネスワイヤ） — 科学サービスの世界的リーダー企業であるサーモフィッシャーサイエンティフィックは、複数のがん兆候から患者由来の腫瘍オルガノイドや、がんオルガノイドを拡張するために特別に開発された初の商用培養液、Gibco™ OncoPro™ 腫瘍オルガノイド培養液キット*のリリースを発表しました。...
View ArticleClik here to view.
Delta-Fly Pharma Inc.: Schedule for the Interim Analysis of the Phase 3 study...
TOKUSHIMA, Japan Following to the previous information on May 15th in 2023 (Phase 3 Study of DFP-10917 in the R/R AML Patients Shall Be Done with the 1st Interim Analysis for NDA Approval. |...
View ArticleClik here to view.
New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May...
TAIPEI PharmaEssentia Corporation (TPEx:6446), a leading fully integrated biopharmaceutical company in Taiwan, today announced the publication of new results from a Phase 2 clinical study with...
View ArticleClik here to view.
CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM)...
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and...
View Article